Cerebellar ataxia and vestibular areflexia syndromes constitute a spectrum of neurodegenerative disorders that primarily affect motor coordination and balance. These conditions are marked by ...

A recent study by a Finnish research group found that, contrary to the information usually taught in medical schools, more than half of the cerebrovascular diseases that caused ataxia were located ...

A new study by the University of Turku and Turku University Hospital in Finland investigated the origin of ataxia in the brain of patients with stroke. A significant number of the stroke lesions in ...

Cerebellum (Latin: "little brain") in orange. Cerebellar means "relating to the cerebellum." Source: 3dMediSphere / Shutterstock Since the 1970s, I've been intrigued by the cerebellum's role in peak ...

Researchers have developed an animal model that reproduces motor dysfunction and cerebellar neurodegeneration similar to that in spinocerebellar ataxia (SCA) by inhibiting chaperone-mediated autophagy ...

Question #1 Dr. John, My wife of 44 years recently has been diagnosed with cerebellar ataxia. This is a rare neurological disorder that effects the motor system. Have you ever heard of it? Most people ...

Cerebellum (Latin for "little brain") in red. Cerebellar means "related to the cerebellum." Source: Life Sciences Databases/Creative Commons (CC-BY-SA-2.1-jp) Beta-frequency deep brain stimulation ...

Dysfunctional neurons in the cerebellum, a brain region that controls motor functions, reduced REM sleep in mice. Previously, the group investigated two models of dystonia, a different motor disorder, ...

Please provide your email address to receive an email when new articles are posted on . Areas of the brain in those with stroke were analyzed for lesion activity and functional connectivity. In 54% of ...

New research from Baylor College of Medicine scientists shows that a combination of deep brain stimulation (DBS) and exercise has potential benefits for treating ataxia, a rare genetic ...

Solid Biosciences announces FDA clearance for SGT-212, targeting Friedreich’s ataxia with dual gene therapy administration routes, initiating Phase 1b trial in 2025. Solid Biosciences Inc. announced ...